CGRP therapy normalises in migraine care
CGRP-class agents have moved from specialty curiosity to routine migraine prevention and acute treatment.
CGRP-targeted therapy in migraine has stopped being novel. Both prevention and acute use have settled into routine practice in primary-care neurology, with the access conversation now about prior authorisation and step therapy more than scientific debate.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is spasticity?
- SnapshotAcute ischemic stroke therapy reference (2026)
- ExplainedAcute ischemic stroke explained
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.